

Genaera

[View the current Genaera Page on BioPortfolio.com](http://www.bioportfolio.com)

(<http://www.bioportfolio.com/biocorporate/4330-Genaera.html>)

Contact Details:

5110 Campus Drive

Plymouth Meeting

PA

19462

United States of America

Tel: (610) 941-4020

Fax: (610) 941-5399

Email: info@genaera.com

Genaera Corporation is a biopharmaceutical company committed to developing medicines for serious diseases from genomics and natural products. Our research and development efforts are focused on anti-angiogenesis, obesity, infectious and respiratory diseases. We were incorporated in the State of Delaware in 1987 as Magainin Pharmaceuticals, Inc. and began operations in 1988. We changed our name to Genaera Corporation on March 9, 2001. Genaera maintains its headquarters and laboratory facilities in Plymouth Meeting, Pennsylvania.

Recent Publications by Genaera:



- [Assessment of renal injury in vivo.](#)
*The ICH S7A (Safety Pharmacology for Human Pharmaceuticals) guidelines...*13th December, 2005
Genaera Corporation, 5110 Campus Drive, Plymouth Meeting, PA 19462, USA.- J Pharmacol Toxicol Methods. 2005 Jul-Aug;52(1):30-45. ([DOI Direct Link](#))
- [Quantitative analysis of squalamine, a self-ionization-suppressing aminosterol sulfate, in human plasma by LC-MS/MS.](#)
*The special physico-chemical property of squalamine enables the formation...*7th October, 2004
Genaera Corporation, 5/10 Campus Drive, Plymouth Meeting, PA 19462, USA.- J Pharm Biomed Anal. 2004 Feb 18;34(3):631-41.
- [Determination of degradation products of squalamine lactate using LC/MS.](#)
*Heat, acid and base stress methods were applied to study the stability of...*6th January, 2004
Genaera Corporation, 5110 Campus Drive, Plymouth Meeting, PA 19462, USA.- J Pharm Biomed Anal. 2003 Apr 24;32(1):85-96.
- [A calcium-activated chloride channel blocker inhibits goblet cell metaplasia and mucus overproduction.](#)
*We have previously shown that expression of a Ca²⁺-activated Cl⁻ channel...*29th May, 2003

BioNews Results for Genaera



- [Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference](#)
Montana's News Station: Dec 4 2008 7:16PM Matching: genaera
- [Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference](#)
Pharma Live: Dec 4 2008 9:12PM Matching: genaera
- [Genaera starts trial of Trodusquemine in overweight and obese type 2 diabetes](#)
News-Medical.Net: Dec 2 2008 2:22PM Matching: genaera
- [Genaera Begins Phase 1b Trial Of Trodusquemine \(MSI-1436\) In Overweight And Obese Type 2 Diabetics](#)
Medical News Today: Dec 2 2008 8:39AM Matching: genaera
- [Genaera Begins Phase 1b Trial of Trodusquemine \(MSI-1436\) in Overweight and Obese Type 2 Diabetics](#)
KSLA: Dec 1 2008 3:12PM Matching: genaera
- [Genaera Begins Phase 1b Trial of Trodusquemine \(MSI-1436\) in Overweight and Obese Type 2 Diabetics](#)
Pharma Live: Dec 1 2008 7:48PM Matching: genaera
- [Genaera's Q3 net loss narrows](#)
Pharmaceutical Business Review: Nov 18 2008 2:34PM Matching: genaera
- [Genaera to Present at BIO-Europe 2008](#)
Pharma Live: Nov 13 2008 5:29PM Matching: genaera
- [Genaera to Present at the Rodman & Renshaw Healthcare Conference](#)
Pharma Live: Nov 6 2008 6:00PM Matching: genaera
- [Genaera's partner MedImmune reports interim data from Phase IIa asthma study](#)
Pharmaceutical Business Review: Nov 1 2008 11:08AM Matching: genaera
- [Phase 2a Data for MEDI-528 Presented at CHEST 2008](#)
PR Newswire: Oct 29 2008 12:39PM Matching: genaera
- [Phase 2a Data for MEDI-528 Presented at CHEST 2008](#)
Pharma Live: Oct 29 2008 1:04PM Matching: genaera
- [Genaera to Present at BIO InvestorForum](#)
Pharma Live: Oct 23 2008 1:54PM Matching: genaera
- [Genaera reports positive data from Phase I study of diabetes and obesity drug](#)
Pharmaceutical Business Review: Oct 8 2008 7:21AM Matching: genaera

Genaera Patents:



- 7410959- [Therapeutic uses for aminosterol compounds](#)
- 6388108- [Aminosterol compounds and uses thereof](#)
- 6576434- [Methods for identification of agents which modulate chloride channel activity](#)
- 6596712- [Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities](#)
- 6602850- [Method of treating asthma using soluble IL-9 receptor variants](#)
- 6645492- [Methods of treating asthma with interleukin-9 receptor antibodies](#)
- 6716603- [Nucleic acids encoding a chloride channel protein](#)
- 6737427- [Mucin synthesis inhibitors](#)
- 6933383- [Regioselective and stereoselective oxidation of fused ring systems useful for the preparation of aminosterols](#)
- 6962909- [Treatment of neovascularization disorders with squalimine](#)
- 7056698- [Nucleic acids encoding interleukin-9 receptor variants](#)
- 7074778- [Asthma associated factors as targets for treating atopic allergies including asthma and related disorders](#)
- 7192578- [Interleukin-9 mutein peptides](#)
- 7208292- [Nucleic acid encoding an interleukin-9 receptor variant](#)
- 7211254- [Methods for treating ICACC protein associated diseases](#)
- 7345051- [Mucin synthesis inhibitors](#)
- 7384767- [Nucleic acid encoding an interleukin-9 receptor variant](#)
- 6261559- [Methods of treating asthma with interleukin-9 antibodies](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical

practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2008 - BioPortfolio Limited.

